Celldex Therapeutics PE Ratio 2010-2022 | CLDX

Current and historical p/e ratio for Celldex Therapeutics (CLDX) from 2010 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Celldex Therapeutics PE ratio as of February 03, 2023 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Celldex Therapeutics PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2023-02-03 46.09 0.00
2022-09-30 28.11 $-2.26 0.00
2022-06-30 26.96 $-2.14 0.00
2022-03-31 34.06 $-1.71 0.00
2021-12-31 38.64 $-1.64 0.00
2021-09-30 53.99 $-1.76 0.00
2021-06-30 33.44 $-1.67 0.00
2021-03-31 20.60 $-1.83 0.00
2020-12-31 17.52 $-2.14 0.00
2020-09-30 14.83 $-2.23 0.00
2020-06-30 13.00 $-2.62 0.00
2020-03-31 1.66 $-2.96 0.00
2019-12-31 2.23 $-3.63 0.00
2019-09-30 2.13 $-3.80 0.00
2019-06-30 2.68 $-3.65 0.00
2019-03-31 4.92 $-4.46 0.00
2018-12-31 2.97 $-15.65 0.00
2018-09-30 6.77 $-15.29 0.00
2018-06-30 7.55 $-17.69 0.00
2018-03-31 34.95 $-19.49 0.00
2017-12-31 42.60 $-11.09 0.00
2017-09-30 42.90 $-15.14 0.00
2017-06-30 37.05 $-16.49 0.00
2017-03-31 54.15 $-17.84 0.00
2016-12-31 53.10 $-18.89 0.00
2016-09-30 60.60 $-19.34 0.00
2016-06-30 65.85 $-19.79 0.00
2016-03-31 56.70 $-19.94 0.00
2015-12-31 235.20 $-19.64 0.00
2015-09-30 158.10 $-20.09 0.00
2015-06-30 378.30 $-19.94 0.00
2015-03-31 418.05 $-19.79 0.00
2014-12-31 273.75 $-19.79 0.00
2014-09-30 194.40 $-18.44 0.00
2014-06-30 244.80 $-18.14 0.00
2014-03-31 265.05 $-16.94 0.00
2013-12-31 363.15 $-15.44 0.00
2013-09-30 531.45 $-15.44 0.00
2013-06-30 234.15 $-14.84 0.00
2013-03-31 173.70 $-14.69 0.00
2012-12-31 100.65 $-15.29 0.00
2012-09-30 94.50 $-15.59 0.00
2012-06-30 77.63 $-15.89 0.00
2012-03-31 76.35 $-16.49 0.00
2011-12-31 39.00 $-17.09 0.00
2011-09-30 34.28 $-2.25 0.00
2011-06-30 53.25 $-2.40 0.00
2011-03-31 60.30 $-2.85 0.00
2010-12-31 61.80 $-1.35 0.00
2010-09-30 60.00 $-18.29 0.00
2010-06-30 68.40 $-20.84 0.00
2010-03-31 92.10 $-24.59 0.00
2009-12-31 70.05 $-28.79 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.171B $0.005B
CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators to create novel disease-specific drug candidates.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00